Camp4 Therapeutics (CAMP) Liabilities and Shareholders Equity (2023 - 2026)

Camp4 Therapeutics has reported Liabilities and Shareholders Equity for 4 years, with the latest figure at $105.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 68.0% year-over-year to $105.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $360.9 million (up 122.19% YoY) and the FY2025 annual result came in at $117.8 million, up 50.44% from the prior year.
• Liabilities and Shareholders Equity slipped to $105.5 million in Q1 2026 per CAMP's latest filing, from $117.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $117.8 million in Q4 2025 and troughed at $21.4 million in Q3 2024.
• A 4-year average of $72.3 million and a median of $70.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity surged 42.52% in 2024, then soared 304.4% in 2025.
• Over 4 years, Liabilities and Shareholders Equity stood at $54.9 million in 2023, then soared by 42.52% to $78.3 million in 2024, then jumped by 50.44% to $117.8 million in 2025, then slipped by 10.48% to $105.5 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $105.5 million, $117.8 million, and $86.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.